PMID- 33850951
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210416
IS  - 2329-0501 (Print)
IS  - 2329-0501 (Electronic)
IS  - 2329-0501 (Linking)
VI  - 21
DP  - 2021 Jun 11
TI  - Acerola exosome-like nanovesicles to systemically deliver nucleic acid medicine 
      via oral administration.
PG  - 199-208
LID - 10.1016/j.omtm.2021.03.006 [doi]
AB  - Extracellular vesicles derived from mammalian cells could be useful carriers for 
      drug delivery systems (DDSs); however, with regard to clinical application, there 
      are several issues to be overcome. Acerola (Malpighia emarginata DC.) is a 
      popular health food. In this study, the feasibility of orally administered 
      nucleic acid drug delivery by acerola exosome-like nanoparticles (AELNs) was 
      examined. AELNs were recovered from acerola juice using an affinity column 
      instead of ultracentrifugation. MicroRNA (miRNA) was sufficiently encapsulated in 
      AELNs by 30-min incubation on ice and was protected against RNase, strong acid, 
      and base treatments. The administration of an AELN/miRNA mixture in cells 
      achieved downregulation of the miRNA's target gene, and this mixture showed 
      cytoplasmic localization. AELNs orally delivered small RNA to the digestive 
      system in vivo. The target gene-suppressing effect in the small intestine and 
      liver peaked 1 day after administration, indicating potential for use as an oral 
      DDS for nucleic acid in the digestive system.
CI  - (c) 2021 The Author(s).
FAU - Umezu, Tomohiro
AU  - Umezu T
AD  - Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
FAU - Takanashi, Masakatsu
AU  - Takanashi M
AD  - Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
FAU - Murakami, Yoshiki
AU  - Murakami Y
AD  - Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
FAU - Ohno, Shin-Ichiro
AU  - Ohno SI
AD  - Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
FAU - Kanekura, Kohsuke
AU  - Kanekura K
AD  - Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
FAU - Sudo, Katsuko
AU  - Sudo K
AD  - Preclinical Research Center, Tokyo Medical University, Tokyo, Japan.
FAU - Nagamine, Kenichi
AU  - Nagamine K
AD  - Research and Development, Global Innovation Center, Nichirei Biosciences inc, 
      Tokyo, Japan.
FAU - Takeuchi, Shin
AU  - Takeuchi S
AD  - Research and Development, Global Innovation Center, Nichirei Biosciences inc, 
      Tokyo, Japan.
FAU - Ochiya, Takahiro
AU  - Ochiya T
AD  - Department of Molecular and Cellular Medicine, Institute of Medical Science, 
      Tokyo Medical University, Tokyo, Japan.
FAU - Kuroda, Masahiko
AU  - Kuroda M
AD  - Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210310
PL  - United States
TA  - Mol Ther Methods Clin Dev
JT  - Molecular therapy. Methods & clinical development
JID - 101624857
PMC - PMC8010214
OTO - NOTNLM
OT  - acerola
OT  - nanovesicle
OT  - nucleic acid medicine
OT  - oral administration
COIS- The authors declare no competing interests.
EDAT- 2021/04/15 06:00
MHDA- 2021/04/15 06:01
PMCR- 2021/03/10
CRDT- 2021/04/14 06:35
PHST- 2020/09/23 00:00 [received]
PHST- 2021/03/06 00:00 [accepted]
PHST- 2021/04/14 06:35 [entrez]
PHST- 2021/04/15 06:00 [pubmed]
PHST- 2021/04/15 06:01 [medline]
PHST- 2021/03/10 00:00 [pmc-release]
AID - S2329-0501(21)00046-2 [pii]
AID - 10.1016/j.omtm.2021.03.006 [doi]
PST - epublish
SO  - Mol Ther Methods Clin Dev. 2021 Mar 10;21:199-208. doi: 
      10.1016/j.omtm.2021.03.006. eCollection 2021 Jun 11.